Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TI-0093 in recurrent/metastatic HPV-16 positive solid tumors
NCT07081984Phase 1Recruiting
- Sponsor
- Therorna
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TI-0093 in Human papillomavirus type 16 positive solid tumor, sponsored by Therorna. Primary endpoints: Adverse Events, Dose-Limiting Toxicities at 3 months and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
TI-0093
03
Conditions
Human papillomavirus type 16 positive solid tumor
Beyond the preview
Go deeper on NCT07081984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081984.